DIRS.INFO The most relevant business & tech news

☆ Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations
▼ + stars: | 2024-04-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A federal judge in New Jersey on Monday rejected Johnson & Johnson 's and Bristol Myers Squibb 's legal challenges to the Biden administration's Medicare drug-price negotiations, ruling that the program is constitutional. J&J and Bristol Myers Squibb did not immediately respond to requests for comment on the ruling. J&J, Bristol Myers Squibb, Novo Nordisk and Novartis presented their oral arguments before Quraishi during the same hearing in March. That same month, a federal judge in Delaware rejected AstraZeneca's separate lawsuit challenging the negotiations. In Texas, a third federal judge tossed a separate lawsuit in February.

Persons: Johnson, Bristol Myers, Joe Biden's, Zahid Quraishi, Quraishi, Bristol Myers Squibb's, AstraZeneca's Organizations: Bristol, Bristol Myers Squibb, Biden, White, Supreme, Final, of New, Novo Nordisk, Novartis, Chamber of Commerce Locations: New Jersey, U.S, of New Jersey, Delaware, Texas, Ohio

☆ Corporate earnings solid so far, despite threats from a slowing economy and sticky inflation
▼ + stars: | 2024-04-29 | by ( Bob Pisani | ) www.cnbc.com time to read: +6 min

Valuations coming down So if earnings are up, why is the S & P off its highs? Today, a month later, 2024 earnings estimates are essentially the same but the multiple has declined to 20.8. The S & P 500 hit a low of 4,117 on Oct. 27 and only recovered when rates came down in early November. There are some big drags on earnings Some companies are seeing large declines in earnings estimates that are weighing on their sectors. When including this one-time item, the S & P 500 earnings growth rate for the first quarter declines to 5.6%, from 8.7%, LSEG has noted.

Persons: Goldman Sachs, JPMorgan Chase, Morgan Stanley, Christopher Suh, Stephen Squeri, Hess, Nick Raich, LSEG, Hal Lawton, Brian Niccol, CNBC's Kate Rogers, Horton, Paul Romanowski, Kimberly, Clark, Michael Hsu Organizations: Companies, Netflix, JPMorgan, GE Aerospace, Caterpillar, Microsoft, Merck, Ford, Waste Management, Royal, Consumer, American Express, Energy, Marathon Petroleum, Apache, Valero Energy, Oil, Occidental Petroleum, Devon Energy, ConocoPhillips, Exxon Mobil, Scout, Bristol Myers Squibb, Karuna Therapeutics, Boeing, Nvidia, Meta, AMD Locations: financials, industrials, Royal Caribbean, North America

☆ Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
▼ + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Bristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth. Two-thirds of savings are associated with drug research and development, Bristol Myers Squibb executives said during an earnings call on Thursday. Those deals come as Bristol Myers faces pressure to launch new drugs and offset the potential loss of revenue from top-selling treatments. Shares of Bristol Myers fell more than 1% in premarket trading Tuesday.

Persons: Bristol Myers, Samit Hirawat, Chris Boerner, Boerner, Revlimid Organizations: Bristol Myers Squibb, Bristol Myers, Karuna Therapeutics, SystImmune, Bristol, LSEG Locations: Cambridge, Cambridge , Massachusetts, Here's

Some companies that are about to report earnings could see a slide in their share prices. With the busiest week of earnings season underway, investors are certainly in for a hectic time. Nearly a third of the companies in the S & P 500 are scheduled to report their earnings this week. CNBC Pro screened the S & P 500 for companies that could see their stocks tumble after earnings. Industrial technology company Rockwell Automation has had its earnings revised downward 29 times in the past three months.

Persons: Myers Squibb, Steve Chesney Organizations: CNBC Pro, Myers, Bristol, Myers Squibb, Rockwell Automation, Gilead Sciences Locations: Bristol, Biopharmaceutical, Gilead

☆ Stock futures fall after Meta Platforms, IBM report quarterly results: Live updates
▼ + stars: | 2024-04-24 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Traders work on the floor of the New York Stock Exchange during afternoon trading on April 09, 2024 in New York City. U.S. stock futures fell on Wednesday night after tech juggernaut Meta Platforms reported its latest quarterly results. S&P 500 futures slid 0.6%, and Nasdaq 100 futures dropped 1.1%. Meta Platforms plunged 15% in extended trading after the social media giant issued second-quarter revenue guidance that was lighter than expected. Fed funds futures trading suggests the first cut could take place at the September Fed meeting, according to CME FedWatch Tool.

Persons: Dow Jones, Anastasia Amoroso, Northrop Grumman, Myers Squibb Organizations: New York Stock Exchange, Traders, Dow Jones, Nasdaq, Business Machines, Dow, Federal, FedWatch, Caterpillar, Honeywell, Northrop, American Airlines, Comcast, Merck, Bristol, Myers, CNBC Locations: New York City . U.S

☆ Novartis lifts guidance after first-quarter results beat expectations
▼ + stars: | 2024-04-23 | by ( ) www.cnbc.com time to read: +2 min

Signage is displayed on the exterior of the Novartis AG Institutes for BioMedical Research building in Cambridge, Massachusetts, U.S., on Friday, Aug. 5, 2016. Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results. In a statement, it said 2024 net sales would likely grow by a high-single to low double-digit percentage with adjusted operating income expected to grow by a low double-digit to mid-teens percentage. It has previously predicted that adjusted operating income would increase by a "high single-digit" percentage with "mid single-digit" sales growth. Quarterly adjusted operating income gained 16% to $4.54 billion, beating an average analyst estimate of about $4.3 billion.

Persons: Bristol Myers, Giovanni Caforio, Joerg Reinhardt, Vas Narasimhan, Sandoz Organizations: Novartis, Institutes, Research, Bristol, Bristol Myers Squibb Locations: Cambridge , Massachusetts, U.S

☆ 6 portfolio stock earnings and the Fed's favorite inflation gauge dominate the week ahead
▼ + stars: | 2024-04-20 | by ( Zev Fima | ) www.cnbc.com time to read: +11 min

The Nasdaq sank 2% on Friday as Netflix dropped nearly 11% post-earnings and Club stock Nvidia fell 10%, entering bear market territory but still up more than 50% in 2024. Following a much stronger-than-expected March retail sales report last month, fresh economic data and six Club stock earnings will take center stage in the week ahead. While lower rates may help stock multiples, that is not a sustainable path to higher equity prices over time. Earnings : The latest quarterly reporting season is starting to ramp into high gear with six Club names set to report next week. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Dow, Jerome Powell, Jim Cramer, Mark, Meta, Bing, Ford, Vimal, Lockheed Martin, Clark, Philip Morris, Sherwin, Williams, Baker Hughes, Lam, Northrop, Dr Pepper, CARR, Edwards Lifesciences, Jim Cramer's, Jim, Michael M Organizations: Nasdaq, Netflix, Nvidia, Dow Jones, Federal, Fed, Hamas, Gross, Google, Reality Labs, General Motors, Honeywell, Microsoft, Verizon Communications, Albertsons Companies, SAP, Cadence Design Systems, United Parcel Service, General Electric, GE, PepsiCo, Lockheed, Spotify Technology, RTX Corporation, JetBlue Airways, Halliburton, HAL, Philip Morris International, Quest Diagnostics, Texas Instruments, Seagate Technology, Mattel, Veralto Corporation, Boeing, General Dynamics, Boston, Hilton, Fisher, Otis Worldwide, IBM, Grill, Viking Therapeutics, Lam Research, Whirlpool, WM, Honeywell International, Royal Caribbean Cruises, American Airlines, Altria, Newmont, Caterpillar, Southwest Airlines, Myers Squibb, AstraZeneca, Mobileye, Northrop Grumman, CNBC, Comcast, Merck, Dow Inc, Carrier Global, Union Pacific, Intel, Western, Mobile, L3Harris Technologies, Exxon Mobil, Chevron, Colgate, Palmolive, HCA Healthcare, Charter Communications, Newell Brands, Jim Cramer's Charitable, Traders, New York Stock Exchange, Santiago, Getty Locations: Israel, Iran, Ukraine, destocking, China, Cleveland, Freeport, McMoRan, Kimberly, Masco, Bristol, New York City

☆ These are the 10 most overvalued stocks in the S&P 500
▼ + stars: | 2024-04-18 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Shares of these companies would be considered overvalued, meaning they're trading at a current price that is not justified by their P/E ratio. Super Micro Computer trades at a 32.9 forward P/E, which is 173% above the five-year average P/E of 12.1. Microchip Technology is trading 73% above its five-year average P/E ratio of 15.8, while Broadcom is trading at a 58% premium. Eli Lilly is another overvalued name, as the stock is trading at a 71% premium to its five-year average. Other expensive stocks included in the list include copper producer Freeport McMoRan , pharmaceutical company Bristol-Myers Squibb and Tyson Foods .

Persons: Dow, Eli Lilly, Mounjaro, Eli Lilly's, Myers Squibb Organizations: Nasdaq, CNBC, Computer, Broadcom, Technology, Micro Computer, Bristol, Myers, Tyson Foods Locations: Freeport

☆ Biotech stocks are ready to break out. They just need one more thing
▼ + stars: | 2024-04-10 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. Last week, Morgan Stanley analysts noted that it is the months leading up to an initial rate cut when biotech stocks outperform. Morgan Stanley also believes the case for biotech stocks is further reinforced by the financing environment and the outlook for mergers and acquisitions as well as upcoming innovation. The case for innovation Morgan Stanley also favors owning biotech stocks that have a strong drug platform even if the key catalyst of clinical trial data and FDA approvals are farther out. Rhythm ranks among the stocks rated overweight that Morgan Stanley favors in this category.

Persons: Morgan Stanley, Needham, Joseph Stringer, dealmaking, Stringer, erosive, it's, Phathom, GERD, LSEG, Merck, — CNBC's Michael Bloom Organizations: Federal Reserve, Nasdaq, Oncology, Immunology, Phathom Pharmaceutical, Pharmaceuticals, Phathom Pharmaceuticals, LSEG, Drug, Bristol Myers Squibb, Pfizer, Intellia Therapeutics, Rocket Pharmaceuticals Locations: New Jersey

But J&J's drug is walking away with a notable edge over its rival. They add more options to a growing arsenal of treatments that have helped improve outcomes for people with multiple myeloma. But the new approvals also give J&J's therapy, which was developed with Legend Biotech, a clear advantage over Bristol Myers's drug. J&J's drug has gradually gained ground over Abecma in the CAR-T market for multiple myeloma, even though it first entered the market a year later. With the new approval on Friday, Jefferies' Shi expects J&J's drug to win the majority of that market share.

Persons: Jonathan Raa, Johnson, Myers's, Bristol Myers, Jefferies, Kelly Shi, Shi, Carvykti, Cantor Fitzgerald, Rick Bienkowski, Kelsey Goodwin, Annika, annikakim.constantino@nbcuni.com Organizations: Nurphoto, Bristol Myers Squibb, Johnson, Food and Drug Administration, FDA, Legend Biotech, Bristol, New York Stock Exchange, NYSE, Reuters, Mount Sinai Hospital, Getty Locations: Bristol, U.S, EU, Japan, Mount Sinai, New York City

☆ MAI Capital's Grisanti offers 3 buys and a bail: Bristol Myers Squibb, Verizon, Hershey & Boeing
▼ + stars: | 2024-04-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMAI Capital's Grisanti offers 3 buys and a bail: Bristol Myers Squibb, Verizon, Hershey & BoeingChris Grisanti, MAI Capital Management chief equity strategist, joins 'The Exchange' to discuss how to trade Bristol Myers Squibb, Verizon, Hershey, and Boeing.

Persons: Boeing Chris Grisanti Organizations: MAI, Grisanti, Bristol Myers Squibb, Verizon, Hershey, Boeing, MAI Capital Management

☆ Sydell L. Miller, Self-Made Eyelash and Hair Care Mogul, Dies at 86
▼ + stars: | 2024-03-14 | by ( Alex Traub | ) www.nytimes.com time to read: +1 min

Sydell L. Miller, a self-made beauty mogul who went from the stay-at-home wife of a Cleveland salon owner to a Palm Beach mansion so immense that it was said to take an hour to walk through all of its rooms, died on Feb. 25 at her home in Cleveland. Her daughter Stacie Halpern confirmed the death. Ms. Miller had various health issues, including serious heart problems dating to the early 1990s; Ms. Halpern said that a combination of factors had recently caused her mother’s health to decline. Ms. Miller and her husband, Arnold Miller, created two dominant brands: Ardell, the industry standard for abundant and shapely false eyelashes, and Matrix Essentials, which has often been described as the nation’s largest manufacturer of salon products and was the primary source of Ms. Miller’s fortune. In 1994, two years after her husband’s death, Bristol Myers Squibb bought Matrix from Ms. Miller for $400 million.

Persons: Miller, Stacie Halpern, Halpern, Arnold Miller Organizations: Bristol Myers Squibb Locations: Cleveland

☆ A lower-cost options trade that wins if this cheap drug stock keeps making a comeback
▼ + stars: | 2024-03-13 | by ( Tony Zhang | ) www.cnbc.com time to read: +3 min

Let's analyze how to trade a drug stock that's made a terrific comeback and could have more upside from here. But there's a catch: The price of call options have become too expensive given the rally, so we need to think of lower-cost trade to bet on upside from here. Now that it's traded off those lows and started to outperform the markets, I have a follow-up trade. The trade Options on BMY currently are very expensive, so buying calls are out of the question. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR.

Persons: that's, BMY, it's Organizations: Myers Squibb, underperformance, pharma, Bristol Myers Locations: Bristol

☆ Judge rejects AstraZeneca’s challenge to Medicare drug price negotiations
▼ + stars: | 2024-03-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A federal judge on Friday rejected AstraZeneca 's legal challenge to Medicare's new power to negotiate the prices of certain costly prescription drugs with manufacturers. The decision is another win for the Biden administration in a bitter legal fight with the pharmaceutical industry over the constitutionality of those price talks. The opportunity to sell drugs to more than 49 million Medicare and Medicaid beneficiaries is a "powerful incentive" for manufacturers to participate in the price talks with the government, Connolly wrote. The ruling comes a month after a federal judge in Texas tossed a separate lawsuit challenging the price talks. On March 7, Bristol Myers Squibb, Novo Nordisk, Novartis and Johnson & Johnson will present their oral arguments to a federal judge in New Jersey in the same hearing.

Persons: AstraZeneca, Biden, AstraZeneca's, Colm Connolly, Connolly, Johnson Organizations: U.S . Department of Health, Human Services, Washington , D.C, Manufacturers, Supreme, District, AstraZeneca, Chamber of Commerce, Bristol Myers Squibb, Novo Nordisk, Novartis, Johnson, CNBC PRO Locations: Washington ,, Delaware, Texas, Ohio, New Jersey

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ Federal judge tosses lobbying group's lawsuit challenging Medicare drug price negotiations
▼ + stars: | 2024-02-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The decision is an early win for the Biden administration as it grapples with a flurry of other legal challenges that drugmakers have filed against the Medicare drug price negotiations. The judge's ruling won't end the legal battle over the policy, which could end up at the Supreme Court. A slate of major companies with drugs selected for negotiations, including J&J, Merck , and Bristol Myers Squibb , have filed separate lawsuits challenging the constitutionality of the price talks. The suit also argued that the price talks violate the Eighth Amendment because they include a "crippling" excise tax aimed at forcing drugmakers to accept the government-dictated price of medicines. The groups also argued that the price talks violate due process by denying pharmaceutical companies and the public input on how Medicare negotiations will be implemented.

Persons: Biden, drugmakers, Judge David Ezra of, Ezra, NICA's, Nicole Longo, PhRMA, Eli Lilly, Johnson, NICA Organizations: U.S . Department of Health, Human Services, Supreme, Medicare, Western, Western District of Texas, Pharmaceutical Research, Manufacturers of America, Global Colon Cancer Association, National, Center Association, CNBC, Pfizer, Johnson, Merck, Bristol Myers Squibb, Chamber of Commerce, Department of Health, Department of Justice Locations: Washington ,, Western District, PhRMA, Ohio

☆ Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing
▼ + stars: | 2024-02-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Senators will question the CEOs of Johnson & Johnson , Merck and Bristol Myers Squibb on U.S. drug prices at a hearing Thursday, as lawmakers on both sides of the aisle work to rein in high health-care costs for Americans. Prescription drug prices in the U.S. are also more than 2.5 times as high as those in other high-income nations, another federal report showed. The Senate Health, Education, Labor and Pensions Committee says that's especially true for some of the top drugs from J&J, Merck and Bristol Myers Squibb. ET and include testimony from J&J CEO Joaquin Duato, Merck CEO Robert Davis and Bristol Myers Squibb CEO Chris Boerner. A spokesperson for Bristol Myers Squibb did not immediately respond to a request for comment ahead of the hearing.

Persons: Sen, Bernie Sanders, Ed Markey, Joaquin Duato, Robert Davis, Chris Boerner, Duato, Davis, Bristol Myers, Eli Lilly's, J Organizations: Capitol, Johnson, Merck, Bristol Myers Squibb, U.S, Health, Education, Labor, Pensions, Bristol Myers, CNBC, J, Bristol Locations: U.S

☆ Under Bernie Sanders’s Glare, Pharmaceutical Chiefs Will Testify on Drug Prices
▼ + stars: | 2024-02-08 | by ( Noah Weiland | Rebecca Robbins | ) www.nytimes.com time to read: +1 min

The chief executives of three major pharmaceutical companies are set to appear in front of the Senate health committee on Thursday to defend how much they charge for drugs in the United States, drawing them further into a confrontation with lawmakers and the Biden administration over the cost of some of the most widely used prescription medications. The three executives scheduled to testify — Joaquin Duato of Johnson & Johnson, Robert M. Davis of Merck and Christopher Boerner of Bristol Myers Squibb — are expected to clash with the health committee’s chairman, Senator Bernie Sanders of Vermont, an independent who has made reining in drug prices a signature cause of his late-career years in Congress. Mr. Sanders plans to focus the hearing on why drug prices are higher in the United States than in other wealthy countries. His staff has singled out several widely used drugs, including Eliquis, a blood thinner made by Bristol Myers Squibb, and Januvia, a diabetes drug from Merck, that can be bought for much less in Canada and Europe than in the United States.

Persons: Biden, — Joaquin Duato, Johnson, Robert M, Davis, Christopher Boerner, Bernie Sanders of, Sanders Organizations: Merck, Bristol Myers Squibb Locations: United States, Bernie Sanders of Vermont, Canada, Europe

☆ These stocks could be the hardest hit if Treasury yields don't come down, says Piper Sandler
▼ + stars: | 2024-02-07 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

If higher Treasury yields persist, Piper Sandler believes certain stocks could see their earnings at risk. The yield on the 10-year Treasury rose as high as 4.16% on Monday after hitting a low around 3.8% last week. The 10-year Treasury was last hovering at the 4.09% level. The firm looked for stocks with a high correlation to the 10-year Treasury yield and downbeat earnings revisions, based on a proprietary EPS revisions ratio. Pharmaceutical stock Bristol-Myers Squibb has a comparatively lower correlation value of 0.188 to the 10-year yield.

Persons: Piper Sandler, Jerome Powell, Russell, Charles Schwab, Myers Squibb Organizations: Federal Reserve, Treasury, Piper, Bank of America, Bank, LSEG, East West Bancorp, West Bancorp, Oil, Pharmaceutical, Bristol, Myers Squibb, Redburn Locations: Bristol

☆ Medicare now negotiating price of drug that costs $7,100 in US vs. $900 in Canada
▼ + stars: | 2024-02-06 | by ( Tami Luhby | ) edition.cnn.com time to read: +3 min

The annual list price of Bristol Myers Squibb’s Eliquis, a blood thinner that reduces the risk of stroke, is $7,100 in the US. Johnson & Johnson’s arthritis drug Stelara carries an annual list price of $79,000 in the US. Johnson & Johnson declined to comment on Sanders’ report. Medicare launches drug price negotiationsOther nations typically pay far less for medications, in large part because their governments often determine the cost. Those who have yet to meet their deductible and the uninsured may have to pay the full list price.

Persons: CNN — Sen, Bernie Sanders, Bristol Myers, it’s, Johnson, Sanders, drugmakers, Biden, Donald Trump, Sanders ’, Bristol Myers Squibb, Merck Organizations: CNN, Bristol, Health, Education, Labor, Pensions, Johnson, Merck, Bristol Myers Squibb, Medicare, Bristol Myers Locations: Japan, Canada, Germany, United Kingdom, France, Vermont

☆ Fourth-quarter earnings are shaping up to be the best of 2023, but there's a catch
▼ + stars: | 2024-02-02 | by ( Robert Hum | ) www.cnbc.com time to read: +1 min

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 1, 2024. Here's how big of a surprise corporate profits have been this earnings season: the fourth-quarter is now shaping up to be the best of 2023. Despite ongoing macroeconomic concerns that have hampered demand and weighed on consumer sentiment, almost halfway into earnings season, profits are clearly coming in far better than anybody expected. Helping companies' bottom lines this round: easing input costs; more emphasis on cost controls and efficiencies; and significantly reduced expectations. LSEG, formerly Refinitiv, is now seeing a nearly 8% rise in earnings growth this season.

Organizations: New York Stock Exchange, Apple, Chevron, Exxon Mobil, Merck, Bristol, Myers Squibb, Energy, Tech Locations: New York City, U.S

☆ Stocks making the biggest premarket moves: Meta, Amazon, Bristol-Myers Squibb, Chevron and more
▼ + stars: | 2024-02-02 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Amazon — The e-commerce giant popped nearly 7% a day after posting an earnings and revenue beat . Revenue came in at $1.56 billion, topping the consensus estimate of $1.45 billion. The company reported $2.48 earnings per share, while analysts polled by LSEG had expected $2.21 per share. Analysts polled by LSEG expected guidance of $8.9 billion in revenue and earnings of $4.18 per share this year. Cinga also raised its full-year revenue outlook to at least $235 billion, topping the consensus estimate of $228.65 billion, per StreetAccount.

Persons: Amazon's, LSEG, Skechers, —, Clorox, Cigna, Cinga, Mattel, Hakyung Kim, Sarah Min, Jesse Pound Organizations: LSEG, Revenue, Myers, Chevron, LSEG . Revenue, Exxon Mobil —, Apple —, Apple, Technology, Journal, Barington, Mattel, Citi, Sea Limited Locations: Bristol, China

☆ Bristol Myers Squibb results top estimates as new drugs post strong sales growth
▼ + stars: | 2024-02-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Bristol Myers Squibb reported quarterly earnings and revenue that topped expectations on Friday as its portfolio of new drugs posted strong sales growth. That group raked in $1.07 billion in sales for the quarter, up 66% from the $645 million for the year-earlier period. While its revenue outlook was in line with Wall Street estimates, it anticipates higher than expected earnings for the year. Analysts surveyed by LSEG expect full-year adjusted earnings of $7 per share and sales growth of 1.9%. Bristol Myers said Eliquis and Opdivo also contributed to the slight sales growth in the fourth quarter.

Persons: Bristol Myers, Revlimid, Eliquis, Opdivo, FactSet Organizations: Bristol Myers Squibb, LSEG, Bristol Myers, Wall, Bristol, Pfizer, Medicare

☆ Stocks making the biggest moves midday: Meta, Apple, Intel, Amazon, Clorox and more
▼ + stars: | 2024-02-02 | by ( Hakyung Kim | ) www.cnbc.com time to read: +4 min

Apple — The iPhone maker's shares inched down 0.3% after Apple provided financial guidance for the current quarter that hinted at weak iPhone sales. Amazon posted $1 in earnings per share on $169.96 billion in revenue, according to LSEG. Analysts polled by LSEG had estimated $8.9 billion in revenue and earnings of $4.18 per share this year. Bristol Myers Squibb — The pharmaceutical stock added 1% after fourth-quarter earnings and revenue at the maker of the Opdivo anti-cancer treatment beat analysts' estimates. ExxonMobil , the largest oil company in the U.S., rose 1% after its fourth-quarter earnings per share topped analysts' estimates.

Persons: LSEG, Cigna, Barbie toymaker, Clorox, —, Alex Harring, Yun Li, Tanaya Macheel, Michelle Fox Organizations: Revenue, Apple, Amazon, Analysts, Bristol Myers Squibb, LSEG . Revenue, Wall, Mattel —, Barington, Mattel, Price, Chevron —, Chevron, LSEG, ExxonMobil, Intel, Street Journal Locations: China, U.S, Ohio

☆ Here are Jim Cramer’s rapid-fire takeaways on 6 stocks in the news Friday
▼ + stars: | 2024-02-02 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +1 min

Clorox – The consumer products giant saw a huge earnings beat. "Things are back online, and there's tremendous demand for their product," Jim said Friday's Morning Meeting rapid fire. Bristol-Myers Squibb – The drugmaker's shares were up after an earnings beat and a higher-than-expected 2024 outlook. "A five-year plan on Bristol Myers," Jim said, unless the company can get more drugs to work out. Jim said, "If you have to own oil, we like Coterra " and own it for the Club.

Persons: Clorox, It's, Jim, Tesla, Elon Musk, Myers Squibb, Bristol Myers, Eli Lilly, they'll Organizations: Myers, CNBC, Exxon, Chevron, Club Locations: Bristol

Search resuls for: "Myers Squibb"

25 mentions found